论文部分内容阅读
[目的]探讨CYP3A5基因多态性与晚期非小细胞肺癌紫杉醇化疗敏感性的关系。[方法]对接受以紫杉醇为基础化疗方案进行化疗的60例晚期非小细胞肺癌患者,采用PCR-RFLP方法检测外周血CYP3A5*1/*3基因多态性,比较不同基因型之间紫杉醇化疗近期疗效的差异。[结果]60例患者中,CYP3A5基因为*1/*1、*1/*3和*3/*3型的患者数分别有6例(10.00%)、20例(33.33%)和34例(56.67%)。*1/*1和*1/*3基因型患者的有效率为19.23%,*3/*3基因型患者的有效率为55.88%,*1/*1和*1/*3基因型患者的有效率明显低于*3/*3基因型患者(P=0.004)。[结论]对非小细胞肺癌患者治疗前进行CYP3A5基因型的测定,可预测紫杉醇的化疗疗效。
[Objective] To investigate the relationship between CYP3A5 gene polymorphism and paclitaxel chemosensitivity in advanced non-small cell lung cancer. [Methods] The polymorphisms of CYP3A5 * 1 / * 3 in peripheral blood were detected by PCR-RFLP in 60 patients with advanced non-small cell lung cancer who were treated with paclitaxel-based chemotherapy. The effects of paclitaxel chemotherapy Recent differences in efficacy. [Results] Sixty patients (10.00%), 20 patients (33.33%) and 34 patients with CYP3A5 gene were found in * 1 / * 1, * 1 / * 3 and * 3 / * (56.67%). The effective rate of patients with * 1 / * 1 and * 1 / * 3 genotypes was 19.23%, that of patients with * 3 / * 3 genotypes was 55.88%, patients with * 1 / * 1 and * 1 / * 3 genotype The effective rate was significantly lower than * 3 / * 3 genotype patients (P = 0.004). [Conclusion] The determination of CYP3A5 genotype in patients with non-small cell lung cancer before treatment can predict the effect of chemotherapy with paclitaxel.